Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager

Inventors

CHAMPION, BRIAN ROBERT • BROMLEY, Alice Claire Noel • FREEDMAN, Joshua David • Fisher, Kerry David • Seymour, Leonard William

Assignees

Akamis Bio Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12049513-B2

Patent

Publication Date

2024-07-30

Expiration Date


Abstract

A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell activator comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.

Core Innovation

The invention relates to a group B oncolytic adenovirus comprising a sequence of formula (I) with a defined genome architecture, including 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR, and specified presence or absence of E1A, E1B, E2B-L1-L2-L3-E2A-L4, E3, E4, and L5. The adenovirus is Enadenotucirev (EnAd) or serotype 11 adenovirus (Ad11), and the transgene at position BY encodes at least one transgene, including a bispecific T cell activator.

The bispecific T cell activator comprises at least two binding domains, with one binding domain specific to CD3 and another binding domain specific to a tumour stromal antigen selected from fibroblast activation protein (FAP), TREM1, IGFBP7, FSP-1, platelet-derived growth factor-α receptor (PDGFR-α), platelet-derived growth factor-β receptor (PDGFR-β), and vimentin. The disclosure also describes specific VH, VL, and scFv embodiments defined by sequence, including SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, and SEQ ID NO: 75.

The document further reports in vitro and ex vivo functional characterization of an engineered Enadenotucirev (EnAd) encoding EpCAM- or FAP-targeting bispecific T-cell activators. It states that viral transgene expression does not impair viral replication or oncolytic activity, and reports activation and selective killing of endogenous EpCAM+ or FAP+ cells in advanced tumor-relevant fluids.

Claims Coverage

The consolidated claim coverage centers on a group B oncolytic adenovirus with a defined sequence architecture and a BY-position transgene encoding a CD3/tumour stromal antigen bispecific T cell activator. In total, the inventive coverage includes the genome architecture, the bispecific engager design, the EnAd or Ad11 limitation, and dependent refinements for replication status, additional transgene count, antigen choice, and sequence embodiments.

Defined group B oncolytic adenovirus genome architecture

A group B oncolytic adenovirus comprising a sequence of formula (I) including 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR, with specified presence or absence of E1A and/or E1B, E2B-L1-L2-L3-E2A-L4, E3, E4, and L5.

Bispecific T cell activator encoded at BY

The transgene in position BY encodes a bispecific T cell activator comprising at least two binding domains, with one binding domain specific to CD3 and one binding domain specific to a tumour stromal antigen selected from FAP, TREM1, IGFBP7, FSP-1, PDGFR-α, PDGFR-β, and vimentin.

Enadenotucirev or serotype 11 adenovirus restriction

The adenovirus is Enadenotucirev (EnAd) or serotype 11 adenovirus (Ad11).

Replication deficient adenovirus

The oncolytic adenovirus is replication deficient.

Additional transgene count

The oncolytic adenovirus encodes 2, 3, or 4 additional transgenes.

Specified VH, VL, and scFv embodiments

The bispecific T cell activator includes a VH domain with the amino acid sequence of SEQ ID NO: 8, a VL domain with the amino acid sequence of SEQ ID NO: 9, or an scFv with the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO: 75.

Tumour stromal antigen selection

The tumour stromal antigen is FAP.

The claim set is anchored by a defined group B oncolytic adenovirus genetic architecture with a BY transgene encoding a CD3-targeting and tumour-stromal-antigen-targeting bispecific T cell activator, limited to Enadenotucirev (EnAd) or serotype 11 adenovirus (Ad11), and further refined by replication, transgene-number, antigen, and sequence limitations.

Stated Advantages

Enhanced tumor selectivity.

Local production/spread of the engager beyond infected cells.

Minimization of off-target effects due to secretion/short half-life.

A two-pronged oncolytic plus immune-activating anti-tumor mechanism.

Transgene expression does not impair viral replication or oncolytic activity.

Antigen-specific T-cell activation and cytotoxicity are reported.

Selective killing of endogenous EpCAM+ or FAP+ cells is reported in advanced tumor-relevant fluids.

Measurable cytokine changes and shifts toward more activated TAM phenotypes are reported in patient-derived exudate environments.

The approach can overcome immune suppression in patient exudate environments.

Documented Applications

Use in cancer treatment as described for an oncolytic plus immune-activating anti-tumor mechanism.

In vitro and ex vivo functional characterization of an engineered Enadenotucirev (EnAd) oncolytic adenovirus encoding EpCAM- or FAP-targeting bispecific T-cell activators.

Assessment of activation and selective killing of endogenous EpCAM+ or FAP+ cells in advanced tumor-relevant fluids including malignant peritoneal ascites and pleural effusions.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.